Squamous Cell Lung CarcinomaSymptoms, Doctors, Treatments, Advances & More
Squamous Cell Lung Carcinoma Overview
Learn About Squamous Cell Lung Carcinoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Henry Ford Cancer-Detroit
Shirish Gadgeel is an Oncologist practicing medicine in Detroit, Michigan. Dr. Gadgeel is rated as an Elite provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Gadgeel is currently accepting new patients.
Enriqueta Felip practices practicing medicine in Barcelona, Spain. Ms. Felip is rated as an Elite expert by MediFind in the treatment of Squamous Cell Lung Carcinoma. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy.
Gustave Roussy
Jean-charles Soria practices practicing medicine in Villejuif, France. Soria is rated as an Elite expert by MediFind in the treatment of Squamous Cell Lung Carcinoma. They are also highly rated in 15 other conditions, according to our data. Their clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy.
Summary: A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
Summary: This study is an open, multicenter, dose-escalation and cohort-expansion non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Lutetium \[177Lu\] BL-ARC001 in patients with locally advanced or metastatic solid tumors.


